Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

IMPORTANCE: KRAS mutations are very common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful. The aim of this trial was to block the MEK and PI3K/AKT pathways downstream of the KRAS protein as an alternate treatment strategy to slow cancer growth and prolon...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Oncol
Auteurs principaux: Chung, Vincent, McDonough, Shannon, Philip, Philip A., Cardin, Dana, Wang-Gillam, Andrea, Hui, Laifong, Tejani, Mohamedtaki A., Seery, Tara E., Dy, Irene A., Baghdadi, Tareq Al, Hendifar, Andrew E., Doyle, L. Austin, Lowy, Andrew M., Guthrie, Katherine A., Blanke, Charles D., Hochster, Howard S.
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5665683/
https://ncbi.nlm.nih.gov/pubmed/27978579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.5383
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires